Allogeneic peripheral blood stem cell collection as of 2008.
The rapid growth of the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to mobilize and collect allogeneic peripheral blood stem cells (PBSCs) for transplantation has made it a new international standard. While the procedure remains safe, older donors, donors with significant comorbidities and pediatric donors are now often employed. This brings a new set of challenges in the donor evaluation, medical clearance, informed consent and collection process. Rare and unexpected severe adverse events related to rhG-CSF administration and PBSC apheresis have been described. Proper PBSC donor counseling, evaluation and care have become even more important.
Rhodes
Beverly
B
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Anderlini
Paolo
P
D001781:Blood Component Removal / Q000379:methods*; D046148:Donor Selection / Q000379:methods*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D019520:Living Donors; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins; D013234:Stem Cells / Q000166:cytology*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor